Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03071536
Other study ID # IRB 317/59
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 25, 2016
Est. completion date May 2027

Study information

Verified date January 2024
Source King Chulalongkorn Memorial Hospital
Contact Suwasin udomkarnjananun, M.D.
Phone 66899679885
Email suwasin.u@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Furosemide is an old drug that has been used frequently in the postoperative period of kidney transplantation, aiming to achieve adequate urine output. There is no previous study that directly evaluate the urine response to standardized dose of furosemide in the postoperative period. The objective is to measure the urine output after standardized dose of furosemide is delivered, as a biomarker to predict the graft function in perioperative period.


Recruitment information / eligibility

Status Recruiting
Enrollment 180
Est. completion date May 2027
Est. primary completion date May 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Deceased donor kidney transplantation at KCMH - informed consent is accepted Exclusion Criteria: - Known allergy to furosemide - Surgical complication of allograft - Urgently needed for dialysis (refractory hypervolemia, uremic symptoms, and hyperkalemia)

Study Design


Intervention

Drug:
Furosemide Injection
Furosemide 1.5 mg/kg intravenously at 3 hours post-reperfusion of kidney allograft

Locations

Country Name City State
Thailand King Chulalongkorn Memorial Hospital Bangkok

Sponsors (1)

Lead Sponsor Collaborator
King Chulalongkorn Memorial Hospital

Country where clinical trial is conducted

Thailand, 

Outcome

Type Measure Description Time frame Safety issue
Primary Urine output Urine output per hour (milliliters/hour) after furosemide injection 6 hours
Secondary Delayed graft function Delayed graft function is defined by the necessity of dialysis within the first week after kidney transplantation. (yes/no) 7 days
Secondary Creatinine reduction ratio Ratio of serum creatinine at postoperative day 7 and 14 to day-zero creatinine At postoperative day 0,7 and 14
See also
  Status Clinical Trial Phase
Completed NCT04369456 - Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients N/A
Recruiting NCT06001320 - De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Trans Recip Early Phase 1
Withdrawn NCT04560582 - Immunosuppression Reduction in Failed Allograft Guided by cfDNA
Not yet recruiting NCT05782543 - Renal Ex Vivo Warm Advanced Resuscitation Through Machine Perfusion N/A
Completed NCT03996551 - ExeRTiOn2- The Weight Gain Prevention Exercise in Renal Transplant Online Study N/A
Recruiting NCT05081141 - HHV8 and Solid Organ Transplantation
Recruiting NCT04508907 - A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients Phase 4
Recruiting NCT06440330 - Define Predictors for Posttransplant Diabetes Mellitus Study
Not yet recruiting NCT06025240 - Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
Recruiting NCT04713774 - Bone Density and Vascular Calcifications Evolution After Renal Transplant
Active, not recruiting NCT05483725 - Immunological Safety and Effectiveness of the First Booster Dose of mRNA Vaccines Against COVID-19 in Kidney Transplant Recipients.
Recruiting NCT06095492 - Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus N/A
Active, not recruiting NCT04207177 - Immunosuppressive Drugs and Gut Microbiome: Pharmacokinetic- and Microbiome Diversity Effects Phase 4
Recruiting NCT03410654 - Assessment of Cognitive Function Before and After Conversion From Immediate Release Tacrolimus to Envarsus XR. Early Phase 1
Completed NCT03373266 - Serun Fluoride and Kidney Transplant Phase 2
Completed NCT04835948 - Efficacy of Single Dose Anti-thymocyte Globulin in the Modulation of T Lymphocytes in Kidney Transplantation
Not yet recruiting NCT04514666 - VOCs in Kidney and Liver Transplants N/A
Recruiting NCT03373500 - Effect of Dietary Salt Reduction on Blood Pressure in Kidney Transplant Recipients N/A
Recruiting NCT05900401 - Delayed Tolerance Through Mixed Chimerism Phase 1/Phase 2
Not yet recruiting NCT05166460 - Novel Cooling Device for the Elimination of Warm Ischemia During Renal Transplantation N/A